| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/04/2002 | US20020086976 Peptide for use in the treatment of autoimmune disease |
| 07/04/2002 | US20020086906 Drugs, cosmetics or dietary supplements; immunomodulation, antiallergens (IgE mediated allergies, e.g., asthma, rhinitis, eczema); anaphylaxis; autoimmune disorders, e.g., Crohn's disease, antiarthritic and ulcer agents; analgesics |
| 07/04/2002 | US20020086904 Methods of treating affective disorders using derivatives of (-)- venlafaxine |
| 07/04/2002 | US20020086899 Treatment of neurotic disorders |
| 07/04/2002 | US20020086882 Regulates immune and inflammatory responses by binding to alpha 4 integrin, also know as Very Late Antigen; antiinflammatory agent |
| 07/04/2002 | US20020086875 Use of nicergoline in the treatment of spasticity |
| 07/04/2002 | US20020086871 Pharmaceutical composition for the treatment of CNS and other disorders |
| 07/04/2002 | US20020086870 Pharmacological treatment for sleep apnea |
| 07/04/2002 | US20020086864 Administering optically pure (S,S) enantiomer of reboxetine |
| 07/04/2002 | US20020086863 New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds |
| 07/04/2002 | US20020086860 For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia |
| 07/04/2002 | US20020086859 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 07/04/2002 | US20020086841 Naked DNA construct encoding a cytokine selected from macrophage inflammatory protein-1 alpha, monocyte chemoattractant protein 1, and tumor necrosis factor-alpha, linked to a viral transcription control sequence, and carrier |
| 07/04/2002 | US20020086832 Immunosuppressing a human after allogenic cell, tissue or organ transplantation by administering a caspase-8 inhibitor |
| 07/04/2002 | US20020086830 (HARC), and polynucleotides which encode it; agonists, antibodies, or antagonists specifically binding HARC, and their use in treating diseases associated with expression of HARC |
| 07/04/2002 | US20020086828 Uses for amino acid anticonvulsants |
| 07/04/2002 | US20020086444 Isolated menbrane protein for use in the diagnosis and treatment of alzheimer's disease |
| 07/04/2002 | US20020086438 Method of preparing delta-9-tetrahydrocannabinol |
| 07/04/2002 | US20020086408 Ubiquitin-like conjugating protein |
| 07/04/2002 | US20020086381 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/04/2002 | US20020086342 Detection of enzyme inhibitors; obtain sample, incubate with modulator, monitor sample for dephosphorylation, compare to control |
| 07/04/2002 | US20020086297 Gene alteration in the gene for the Gbeta3-subunit of the human G protein |
| 07/04/2002 | US20020086282 Methods and compositions for detecting compounds that modulate inflammatory responses |
| 07/04/2002 | US20020086067 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses |
| 07/04/2002 | US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating |
| 07/04/2002 | US20020086049 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 07/04/2002 | US20020086015 Compositions and methods for promoting nerve regeneration |
| 07/04/2002 | US20020085615 Differential scanning calorimeter |
| 07/04/2002 | US20020084230 Methods for screening drugs to predict tardive dyskinesia |
| 07/04/2002 | DE10064453A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases |
| 07/04/2002 | DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases |
| 07/04/2002 | DE10059144A1 Modulation der Transkription pro-inflammatorischer Genprodukte Modulating the transcription of pro-inflammatory gene products |
| 07/04/2002 | DE10044649A1 Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine Substituted 4-phenyl-1- (1-phenylcyclohexyl) -1,2,3,6-tetrahydropyridines |
| 07/04/2002 | CA2847458A1 Defects in periaxin associated with myelinopathies |
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2433520A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | CA2433100A1 Indole derivatives as ligands of thyroid receptors |
| 07/04/2002 | CA2432977A1 New use of artemin, a member of the gdnf ligand family |
| 07/04/2002 | CA2432683A1 Screening method based on siah-numb interaction |
| 07/04/2002 | CA2432661A1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands |
| 07/04/2002 | CA2432654A1 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 07/04/2002 | CA2432543A1 Combination drugs |
| 07/04/2002 | CA2432473A1 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders |
| 07/04/2002 | CA2432214A1 Gene involved in apoptosis regulation |
| 07/04/2002 | CA2432008A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 07/04/2002 | CA2431916A1 New therapeutic uses of smr1 peptides |
| 07/04/2002 | CA2431913A1 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 07/04/2002 | CA2431883A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 07/04/2002 | CA2430719A1 A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 07/04/2002 | CA2429773A1 Aerogel powder comprising therapeutic agents |
| 07/04/2002 | CA2399280A1 Defects in periaxin associated with myelinopathies |
| 07/03/2002 | EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) |
| 07/03/2002 | EP1219624A1 Remedies for neuropathic pain and model animals of neuropathic pain |
| 07/03/2002 | EP1219623A1 New esters derived from substituted phenyl-cyclohexyl compounds |
| 07/03/2002 | EP1219622A2 Pharmaceutical compositions for CNS and other disorders |
| 07/03/2002 | EP1219621A1 Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient |
| 07/03/2002 | EP1219600A1 Prostaglandin derivatives |
| 07/03/2002 | EP1219594A1 New esters derived from substituted phenyl-cyclohexyl compounds |
| 07/03/2002 | EP1219295A1 Controlled release formulation of valproate |
| 07/03/2002 | EP1218544A1 Methods for identifying rna binding compounds |
| 07/03/2002 | EP1218518A1 Dna polymerase lambda and uses thereof |
| 07/03/2002 | EP1218516A2 Method for preparing steroids modified by yeast fermentation |
| 07/03/2002 | EP1218515A2 Regulation with binding cassette transporter protein abc1 |
| 07/03/2002 | EP1218511A1 Antimicrobial compositions |
| 07/03/2002 | EP1218509A2 Fibroblast growth factor-like polypeptides |
| 07/03/2002 | EP1218502A2 Nicotinic acetylcholine receptor : alpha10 subunit |
| 07/03/2002 | EP1218491A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218408A1 32 human secreted proteins |
| 07/03/2002 | EP1218403A2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 07/03/2002 | EP1218397A1 Attractin-like polynucleotides, polypeptides, and antibodies |
| 07/03/2002 | EP1218393A1 Cell targeting compositions and methods of using the same |
| 07/03/2002 | EP1218383A2 Bicyclic imidazo-5-yl-amine derivatives |
| 07/03/2002 | EP1218382A2 Bicyclic imidazo-3-yl-amine derivatives |
| 07/03/2002 | EP1218381A2 AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218380A2 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
| 07/03/2002 | EP1218379A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218378A2 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 07/03/2002 | EP1218377A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
| 07/03/2002 | EP1218375A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 07/03/2002 | EP1218374A1 Pharmaceutically active sulfonamide derivatives |
| 07/03/2002 | EP1218372A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 07/03/2002 | EP1218371A2 Di-substituted iminoheterocyclic compounds |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1218359A2 Piperazine compounds |
| 07/03/2002 | EP1218358A1 Therapeutic quinazoline compounds |
| 07/03/2002 | EP1218352A1 Benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity |
| 07/03/2002 | EP1218347A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 07/03/2002 | EP1218346A1 Pyrazole derivatives |
| 07/03/2002 | EP1218333A1 Anti-inflammatory nitro- and thia- fatty acids |
| 07/03/2002 | EP1218049A2 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 07/03/2002 | EP1218023A2 Method for calming human beings using personal care compositions |
| 07/03/2002 | EP1218013A2 Phospholipid prodrugs of anti-proliferative drugs |
| 07/03/2002 | EP1218010A2 1,4-benzothiazepines to treat obesity related disorders |
| 07/03/2002 | EP1218009A1 Quetiapine granules |
| 07/03/2002 | EP1218008A2 New use of 1,2,4-triazolo[1,5-a]pyrimidines |
| 07/03/2002 | EP1218000A1 Anti-cancer nitro- and thia-fatty acids |
| 07/03/2002 | EP1217996A1 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| 07/03/2002 | EP1217994A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 07/03/2002 | EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery |